Drug intelligence / Profile preview

SYS6012

Development stage: Unknown
Lead developer: CSPC Megalith Biopharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

SYS6012 is a biosimilar to secukinumab, developed by CSPC Megalith Biopharmaceutial. It is a monoclonal antibody that targets interleukin-17A (IL-17A), a cytokine involved in the inflammatory process underlying several autoimmune diseases. By binding to and inhibiting IL-17A, SYS6012 reduces inflammation and related symptoms. The drug is administered via subcutaneous injection and has been evaluated for pharmacokinetic similarity, safety, and immunogenicity compared to the original secukinumab product. Its primary indication under investigation is moderate to severe plaque psoriasis[1][4].

Other names: secukinumab biosimilar

Targets

IL-17A (Interleukin-17A)

Beyond the preview

Go deeper on SYS6012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYS6012.

Explore the full profile